Median Technologies, developer of eyonis, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a provider of AI-enhanced and central imaging services for oncology drug developers, has announced the appointment of Oran Muduroglu as President of Median eyonis Inc., Median’s U.S. subsidiary.
Muduroglu will lead the U.S. launch and scale-up of eyonis LCS, the Company’s AI-powered Software as a Medical Device (SaMD) for lung cancer screening, following the FDA clearance. Oran will continue to serve as Executive Chairman of the Board of Directors of Median Technologies while assuming operational leadership of U.S. commercialisation.
“With FDA clearance secured, a defined Medicare reimbursement pathway in place, and a uniquely differentiated solution developed through the exceptional scientific and engineering leadership of our colleagues in France, we are entering this launch with strong momentum,” said Oran.
Oran continued: “Our focus now is disciplined execution — aligning payers, distribution partners, and providers around a solution that directly addresses one of the key drivers of non-adherence in lung cancer screening. By reducing uncertainty and false positives, we seek to enable earlier diagnosis, improve physician productivity, and strengthen both the clinical and economic performance of screening programs.
“We believe eyonis LCS can materially improve patient confidence and engagement and help health systems focus on patients who truly require intervention. That combination of clinical performance and economic value will drive adoption at scale.”
Oran brings more than three decades of experience building, engineering, and scaling enterprise imaging and workflow platforms, consistently translating technical innovation into broad U.S. adoption.
He led the sale of Cemax to 3M/Imation in 1995, helping accelerate the transition to modern Picture Archiving and Communication Systems (PACS). He later co-founded Stentor, acquired by Philips in 2005, which became one of the first enterprise platforms enabling fully digital imaging workflows and an early SaaS model in medical imaging, reaching the number two U.S. market position within three years.
Further, as CEO of Medicalis, acquired by Siemens Healthineers in 2017, he led commercialisation of a clinical decision support and workflow platform adopted by approximately nine of the top 15 U.S. health systems. In 2018, Alphabet’s Verily recruited him to lead development of a value-based care platform supporting physician groups in managing Medicare Advantage risk.
Across these ventures, Oran has led complex national deployments requiring deep Electronic Medical Records (EMR) and PACS interoperability, rigorous product development, disciplined enterprise sales, and alignment with evolving reimbursement models, experience directly relevant to the U.S. launch of eyonis LCS.
“Oran is a highly respected leader with deep operational rigor and commercialisation expertise,” said Fredrik Brag, CEO and founder of Median Technologies. “His experience scaling imaging platforms nationally makes him uniquely qualified to lead this next phase of growth.”
Following eyonis LCS’ FDA 510(k) clearance, Median has activated a phased U.S. launch strategy designed for disciplined national expansion. The company says it has conducted detailed customer and payor mapping to prioritise regions with strong lung cancer screening volumes and favourable reimbursement dynamics.
To support the launch strategy, Median eyonis Inc. is expanding its U.S.-based commercial and clinical support teams and will deploy a coordinated strategy designed to combine direct enterprise sales, strategic distribution partnerships, and seamless workflow integration.
